The Trump administration is working to lower drug prices for Americans, among other moves that will improve healthcare, according to an op-ed co-authored by HHS Secretary Alex Azar and White House domestic policy chief Joe Grogan in the New York Post, a right-leaning tabloid newspaper.
The message comes after Politico reported relationships between Mr. Azar and Mr. Grogan and other White House policy officials were wearing thin.
The Azar-Grogan op-ed recounts steps President Donald Trump and his administration have taken to address the ills of the U.S. healthcare system, including President Trump's recent executive order on price transparency and a rule to expand health reimbursement arrangements, as well as expedited generic drug approvals and other drug pricing efforts.
"President Trump has promised a better vision: a healthcare system that treats you like a person, not a number," the pair wrote. "He wants to hold providers and Big Pharma accountable to transparency and reasonable prices. We are working every day to protect American patients and deliver on the president's vision."
The Politico report, based on anonymous interviews with a dozen officials, alleged the tensions between HHS and the White House had stalled drug-pricing policy.
More articles on leadership and management:
Methodist Le Bonheur CEO: Reports misrepresent financial assistance programs
Newark Beth Israel, Children's Hospital of New Jersey names board chair
Trump administration delays 'conscience protection' rule for healthcare workers